Clinical portrait of a patient with acute decompensation of heart failure
Authors:
Company:
1Kemerovo State Medical University, Kemerovo, Russian Federation
2Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
3Kuzbass Clinical Cardiology Dispensary named after Academician L.S. Barbarash, Kemerovo, Russian Federation
For correspondence: Sign in or register.
Type: Original articles
DOI:
For citation: Okunev I.M., Kochergina А.М., Kashtalap V.V., Barbarash О.L. Clinical portrait of a patient with acute decompensation of heart failure. Creative Cardiology. 2022; 16 (3): 385–93 (in Russ.). DOI: 10.24022/1997-3187-2022-16-3-385-393
Received / Accepted: 07.06.2022 / 26.08.2022
Keywords: heart failure acute decompensation of heart failure comorbidity adherence to drug therapy
Abstract
Objective. To study the clinical and anamnestic characteristics and adherence to prehospital drug therapy in patients with acute decompensated heart failure (ADHF).
Material and methods. 315 patients admitted to the Department of Emergency Cardiology No. 2 of the Kuzbass Clinical Cardiology Dispensary named after Academician L.S. Barbarash in 2020. The assessment of clinical and anamnestic features of patients and adherence to drug therapy was performed.
Results. The average age was 68.28 ±12.19 years, the proportion of men was 51.11% (n =161). Arterial hypertension was detected in 89.2% (n = 281), previously suffered myocardial infarction 33.33% (n =105), atrial fibrillation in 74.29% (n = 234) patients; dilated cardiomyopathy – in 4.44% (n =14) and heart defects – in 27.3% (n = 86). Active smokers were 9.52% (n = 30) of patients. The most common comorbid disease was type 2 diabetes mellitus (DM2) 27.94% (n = 88). Almost half of patients with ADHF (45.39%, n = 143) have preserved left ventricular ejection fraction (LVEF), moderately reduced LVEF – 20.32% (n = 64), reduced LVEF – 34.28% (n = 108). More than a third (36.83%, n = 116) had signs of anemia of varying severity. Adherence to drug therapy at the prehospital stage was low. Beta-blockers received 53.33% (n = 168) of patients, statins – 33.33% (n = 105), angiotensin-converting enzyme inhibitors – 22.54% (n = 71) of patients, sartans – 19.68% (n = 62), loop diuretics – 43.81% (n = 138) of patients, mineralocorticoid receptor antagonists – 24.44% (n = 77) of patients. None of the patients received angiotensin receptor and neprilysin inhibitor (ARNI) preparations. Inhibitors of sodiumdependent glucose cotransporter type 2 were taken only by 2 patients with concomitant DM2.
Conclusion. Patients hospitalized with ADHF are characterized by a high incidence of anemia and type 2 diabetes, as well as low adherence to the main groups of drug therapy that affects the prognosis.
References
- Groenewegen A., Rutten F.H., Mosterd A., Hoes W. Epidemiology of heart failure. Eur. J. Heart Fail. 2020; 22 (8): 1342–56. DOI: 10.1002/ejhf.1858
- Virani S.S., Alonso A., Benjamin E.J., Bittencourt M.S., Callaway C.W., Carson A.P. et al. Heart disease and stroke statistics – 2020 update: a report from the American Heart Association. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2020; 141 (9): 139–596. DOI: 10.1161/CIR.0000000000000757
- Kitakata H., Kohno T., Kohsaka S., Shiraishi Y., Parizo J.T., Niimi N. et al. Prognostic implications of early and midrange readmissions after acute heart failure hospitalizations: a report from a Japanese multicenter registry. J. Am. Heart Ass. 2020; 9 (10): 9:e014949. DOI: 10.1161/JAHA.119.014949
- Larina V.N., Leonova M.V., Bondarenkova A.A., Larin V.G. Patient compliance and physicians’ adherence to guidelines on heart failure with reduced ejection fraction. Cardiovascular Therapy and Prevention. 2020; 19 (2): 2398 (in Russ.). DOI: 10.15829/1728-8800-2020-2398
- McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M. et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021; 42 (36): 3599–726. DOI: 10.1093/eurheartj/ehab368
- Drapkina O.M., Shishkova V.N., Berns S.A., Gorshkov A.Yu., Ryzhakova L.N., Ivanova A.A. et al. Vaccination against new coronavirus infection in patients with cardiovascular and autoimmune diseases. Complex Issues of Cardiovascular Diseases. 2021; 10 (4): 112–21 (in Russ.). DOI: 10.17802/2306-1278-2021-10-4-112-121
- Sitnikova M.Yu., Lyasnikova E.A., Yurchenko A.V., Trukshina M.A., Kuular A.A., Galenko V.L. et al. Results of 3 years work of the Russian hospital register of chronic heart failure (RUssian hoSpital Heart Failure Registry – RUS-HFR): relationship between management and outcomes in patients with chronic heart failure. Kardiologiia. 2018; 58 (10S): 9–19 (in Russ.). DOI: 10.18087/cardio.2483
- Arutyunov A.G., Rylova A.K., Arutyunov G.P. The register of hospitalized patients with decompensation of blood circulation (Pavlovsky register). Message 1. Modern clinical characteristics of a patient with decompensation of blood circulation. Clinical phenotypes of patients. Journal of Heart Failure. 2014; 82 (1): 23–31 (in Russ.).
- Yancy C.W., Lopatin M., Stevenson L.W., De Marco T., Fonarow G.C.; ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol. 2006; 47 (1): 76–84. DOI: 10.1016/j.jacc.2005.09.022
- Paolillo S., Scardovi A.B., Campodonico J. Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. Eur. J. Prev. Cardiol. 2020; 27 (2): 27–34. DOI: 10.1177/2047487320960288
- Groenveld H.F., Januzzi J.L., Damman K., van Wijngaarden J., Hillege H.L., van Veldhuisen D.J., van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2008; 52 (10): 818–27. DOI: 10.1016/j.jacc.2008.04.061
- Anand I.S., Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018; 138 (1): 80–98. DOI: 10.1161/CIRCULATIONAHA.118.030099
- Samoilova E.V., Fatova M.A., Mindzaev D.R., Zhitareva I.V., Zhirov I.V., Nasonova C.N. et al. Diagnostic prediction models of stratifying chronic heart failure patients based on the underlying disease. Complex Issues of Cardiovascular Diseases. 2021; 10 (1): 6–15 (in Russ.). DOI: 10.17802/2306-1278-2021-10-1-6-15
- Bunova S.S., Zhernakova N.I., Skirdenko Yu.P., Nikolaev N.A. Adherence to therapy, lifestyle modification and medical support of cardiovascular patients. Cardiovascular Therapy and Prevention. 2020; 19 (6): 38–42 (in Russ.). DOI: 10.15829/1728-8800-2020-2665
- Martsevich S.Yu., Guseynova E.T., Kutishenko N.P., Lukina Yu.V., Tolpygina S.N., Voronina V.P., Blagodatskikh S.V. Evaluating adherence to medical therapy in patients with chronic heart failure: design and first results of the COMPLIANCE Study. Rational Pharmacotherapy in Cardiology. 2020; 16 (4): 571–8 (in Russ.) DOI: 10.20996/1819-6446-2020-08-11
About Authors
- Igor’ M. Okunev, Cardiologist, Postgraduate; ORCID
- Anastasiya M. Kochergina, Cand. Med. Sci., Assistant Professor, Researcher; ORCID
- Vasiliy V. Kashtalap, Dr. Med. Sci., Professor of Chair, Head of Department; ORCID
- Ol’ga L. Barbarash, Dr. Med. Sci., Chief of Chair, Academician of Russian Academy of Sciences, Director; ORCID